EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

β2-microglobulin is superior to lactate dehydrogenase and bulky disease for risk stratification in diffuse large B-cell lymphoma patients with IPI 1–2

Hung Chang, Yu-Shin Hung, Ming-Chung Kuo, Tung-Liang Lin, Hsiao-Wen Kao, Hsuan-Jen Shih, Yi-Jiun Su, Yuen-Chin Ong, Ning-Chun Chen

Annals of Hematology · 2026

DOI: 10.1007/s00277-026-07134-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2026. Verfasst von Hung Chang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Chang Gung University, Taoyuan, Taiwan. horng@adm.cgmh.org.tw. Hauptthemen laut MEDLINE: beta 2-Microglobulin, Lymphoma, Large B-Cell, Diffuse, L-Lactate Dehydrogenase, Biomarkers, Tumor. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chang Gung Memorial Hospital, Linkou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The International Prognostic Index (IPI) is the classical assessment tool to evaluate prognosis of diffuse large B cell lymphoma (DLBCL). Although the IPI is simple, reproducible, well validated and widely utilized, it is not entirely accurate in some patients with DLBCL. Recently, it was reported that a subgroup of high-risk DLBCL patients with IPI score 1 or 2 can be identified by bulky disease and high lactate dehydrogenase (LDH) levels. Such classification of high-risk DLBCL has been used in new clinical trials. We analyzed out cohort database to validate such a sub-classification and further evaluated subdivision by serum β2-microglobulin levels. We retrieved the list of patients with new diagnosis of DLBCL between 2015 and 2019 from the Chang Gung Memorial Hospital in Linkou. Consecutive cases were enrolled without a pre-set sample size assessment. For each patient, the IPI was calculated according to published literature. Patients with an IPI score of 1 and 2 were included for this analysis. High-risk DLBCL was defined as bulky tumors (> 7 cm) or high LDH levels (> 1.3-fold upper limit). Serum β2-microglobulin levels were measured in the clinical laboratory. Analyses were done by comparing patients with or without high-risk features as well as patients with or without high β2-microglobulin levels (≥ 3000 µg/L). In 523 patients with DLBCL, 238 had an IPI score of 1–2, and 234 (115 male and 119 female) had sufficient data for high-risk DLBCL sub-classification. The median age was 64 years (range 26 to 90 years). Blood level of β2-microglobulin correlated with that of LDH (r2 = 0.03, p = 0.0136). There was no difference in β2-microglobulin levels between patients with and without bulky tumors ( p = 0.3573). Using LDH > 1.3-fold upper limit as the cutoff, patients with high LDH had significantly higher levels of β2-microglobulin ( p = 0.0096). Sixty-seven patients had high-risk features, defined by high LDH or bulky disease. These patients have significantly higher β2-microglobulin levels ( p = 0.0173). However, in clinical outcome, high-risk and low-risk DLBCL do not differ significantly in progression-free survival ( p = 0.8794) or overall survival ( p = 0.4464). Using 3000 µg/L as a cutoff, patients with high β2-microglobulin levels had significantly shorter progression-free survival ( p = 0.0183) than those with low levels. The difference in overall survival between high and low-level β2-microglobulin did not reach statistical significance ( p = 0.2044). Our experience suggests the high-risk sub-classification based on LDH and bulky disease among patients with an IPI score of 1 or 2 does not correlate with clinical outcomes. In contrast, high levels of β2-microglobulin may help identify a sub-group of high-risk patients. This biomarker may be helpful in refining treatment plans or designing future clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta 2-MicroglobulinLymphoma, Large B-Cell, DiffuseL-Lactate DehydrogenaseBiomarkers, TumorHumansFemaleMaleMiddle AgedAgedAdultRisk AssessmentAged, 80 and overPrognosisAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Bulky diseaseDLBCLInternational prognostic indexLDHβ2-microglobulin

Substanzen

beta 2-MicroglobulinL-Lactate DehydrogenaseB2M protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • School of Medicine, Chang Gung University, Taoyuan, Taiwan. horng@adm.cgmh.org.tw.
  • Division of Hematology, Chang Gung Memorial Hospital, Linkou, Taiwan. horng@adm.cgmh.org.tw.
  • Center of Hemophilia and Coagulation Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan. horng@adm.cgmh.org.tw.
  • Division of Hematology-Oncology, Chang Gung Memorial Hospital, 5 Fu-Shing Street, Kweishan, Taoyuan, 333, Taiwan. horng@adm.cgmh.org.tw.
  • School of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Division of Hematology, Chang Gung Memorial Hospital, Linkou, Taiwan.

Förderung

  • Chang Gung Memorial Hospital, Linkou

Zitieren

APA

Chang, H., Hung, Y. S., Kuo, M. C., Lin, T. L., Kao, H. W., Shih, H. J., Su, Y. J., Ong, Y. C., & Chen, N. C. (2026). β2-microglobulin is superior to lactate dehydrogenase and bulky disease for risk stratification in diffuse large B-cell lymphoma patients with IPI 1–2. Annals of Hematology. https://doi.org/10.1007/s00277-026-07134-6

Vancouver

Chang H, Hung YS, Kuo MC, Lin TL, Kao HW, Shih HJ, et al. β2-microglobulin is superior to lactate dehydrogenase and bulky disease for risk stratification in diffuse large B-cell lymphoma patients with IPI 1–2. Annals of Hematology. 2026. doi:10.1007/s00277-026-07134-6

BibTeX
@article{Chang2026,
  author = {Chang, Hung and Hung, Yu-Shin and Kuo, Ming-Chung and Lin, Tung-Liang and Kao, Hsiao-Wen and Shih, Hsuan-Jen and Su, Yi-Jiun and Ong, Yuen-Chin and Chen, Ning-Chun},
  title = {β2-microglobulin is superior to lactate dehydrogenase and bulky disease for risk stratification in diffuse large B-cell lymphoma patients with IPI 1–2},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-07134-6}
}
Kostenlos starten →